Literature DB >> 4092724

Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.

M Stäubli, A Troendle, B Schmid, P Balmer, B Kohler, H Studer, J Bircher.   

Abstract

In 23 patients treated with the iodine-containing antiarrhythmic drug amiodarone, the plasma concentrations of amiodarone, desethylamiodarone and iodine have been studied. Besides amiodarone and desethylamiodarone, a pool of iodine-containing substances, NANDAI (non-amiodarone-, non-desethylamiodarone-iodine), was present. At steady state the iodine content of NANDAI amounted to 64% and the iodine content of amiodarone plus desethylamiodarone to 36% of total serum iodine. At steady state 26% of the NANDAI fraction was made up of inorganic iodide, the average plasma concentration of which was at least 40 times above the upper limit of the normal range. The serum elimination half-life of NANDAI of 57-160 days exceeded that of amiodarone (35-68 days) and of desethylamiodarone (31-110 days). At steady state the serum concentration of desethylamiodarone appears to be related to the concentration of amiodarone by a Michaelis-Menten type function, yielding a Km of amiodarone of 2.45 mumol/l and a maximal desethylamiodarone concentration of 3.61 mumol/l.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4092724     DOI: 10.1007/BF00613455

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Iodine determination in biological material. Kinetic measurement of the catalytic activity of iodide.

Authors:  K Lauber
Journal:  Anal Chem       Date:  1975-04       Impact factor: 6.986

2.  Side effects of long-term amiodarone therapy.

Authors:  L Harris; W J McKenna; E Rowland; D W Holt; G C Storey; D M Krikler
Journal:  Circulation       Date:  1983-01       Impact factor: 29.690

3.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Pharmacokinetics of amiodarone after intravenous and oral administration.

Authors:  F Andreasen; H Agerbaek; P Bjerregaard; H Gøtzsche
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

5.  Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy.

Authors:  E Martino; M Safran; F Aghini-Lombardi; R Rajatanavin; M Lenziardi; M Fay; A Pacchiarotti; N Aronin; E Macchia; C Haffajee
Journal:  Ann Intern Med       Date:  1984-07       Impact factor: 25.391

6.  Iodine-induced thyrotoxicosis in apparently normal thyroid glands.

Authors:  J C Savoie; J P Massin; P Thomopoulos; F Leger
Journal:  J Clin Endocrinol Metab       Date:  1975-10       Impact factor: 5.958

7.  Clinical efficacy of amiodarone as an antiarrhythmic agent.

Authors:  M B Rosenbaum; P A Chiale; M S Halpern; G J Nau; J Przybylski; R J Levi; J O Lázzari; M V Elizari
Journal:  Am J Cardiol       Date:  1976-12       Impact factor: 2.778

8.  Amiodarone kinetics after oral doses.

Authors:  R Kannan; K Nademanee; J A Hendrickson; H J Rostami; B N Singh
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

9.  Iodine-induced thyrotoxicosis: analysis of eighty-five consecutive cases.

Authors:  A F Leger; J P Massin; M F Laurent; M Vincens; M Auriol; O B Helal; G Chomette; J C Savoie
Journal:  Eur J Clin Invest       Date:  1984-12       Impact factor: 4.686

10.  [Amiodarone and the thyroid gland].

Authors:  M Stäubli; P Bischof; C Wimpfheimer; H Studer
Journal:  Schweiz Med Wochenschr       Date:  1981-10-24
View more
  5 in total

1.  Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole.

Authors:  O Van Reeth; C Decoster; J Unger
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions.

Authors:  K Ohyama; M Nakajima; M Suzuki; N Shimada; H Yamazaki; T Yokoi
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

Review 3.  Amiodarone in the aged.

Authors:  Meera Srinivasan; Laura Ahmad; Ravinay Bhindi; Usaid Allahwala
Journal:  Aust Prescr       Date:  2019-10-01

4.  A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker methodology.

Authors:  Anita Arya; John Silberbauer; Sam L Teichman; Peter Milner; Neil Sulke; A John Camm
Journal:  Europace       Date:  2009-01-26       Impact factor: 5.214

5.  Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions.

Authors:  Mirjam Hempenius; Rolf H H Groenwold; Anthonius de Boer; Olaf H Klungel; Helga Gardarsdottir
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-08-02       Impact factor: 2.890

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.